Most people on weight loss drugs are spending less on restaurants and takeout, survey says

A recent Morgan Stanley survey reveals that most people using GLP-1 medications are cutting back on dining out and takeout. This suggests a shift in spending habits towards healthier choices. Additionally, a smaller portion of respondents reported cutting back on grocery expenses. These results raise concerns regarding the potential impact of increased demand for GLP-1s. Moreover, they highlight the profitability challenges for major restaurant chains and food manufacturers. Furthermore, the survey revealed that individuals on weight loss drugs are more mindful of their food choices and portion sizes. The survey’s findings illuminate the impact of weight loss drugs on both physical health and food-related behaviors. Additionally, they highlight changes in spending patterns.

Most people taking those medications, called GLP-1s, say they are spending less on eating out at restaurants and ordering takeout, according to a Morgan Stanley survey released on Tuesday. A smaller share of those surveyed say they are tightening their purse strings in the grocery store.

The rising demand for these four drugs isn’t expected to ease anytime soon. In the new survey, Morgan Stanley analysts said they expect the market for GLP-1s to be worth $105 billion by 2030. They also estimate that 31.5 million people, or around 9% of the U.S. population, will take GLP-1s by 2035. 

There is growing evidence that the drugs have a meaningful impact on consumer behavior and spending on groceries and restaurants,” Morgan Stanley analysts said in the survey. “All of these dynamics suggest GLP-1 drugs’ impact across consumer sectors is set to increase as drug uptake grows and the drugs reshape behavior among a demographic group that represents a disproportionate share of calorie consumption.”
read more
image source